Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Express Scripts
AstraZeneca
McKesson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Aventis Pharma S.A. v. Apotex Inc. (D. Del. 2008)

See Plans and Pricing

« Back to Dashboard

Aventis Pharma S.A. v. Apotex Inc. (D. Del. 2008)

Docket   Start Trial Date Filed 2008-08-08
Court District Court, D. Delaware Date Terminated 2010-10-20
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties APOTEX CORP.; APOTEX INC.; AVENTIS PHARMA S.A.; SANOFI-AVENTIS US LLC
Patents 4,814,470; 5,403,858; 5,438,072; 5,698,582; 5,714,512; 5,750,561
Attorneys Kirran Bari; Luke Anderson; Matt Neiderman; Monique M. Mendez; Richard T. Ruzich; Richard W. McLaren , Jr.; Steven J. Balick; Tiffany Geyer Lydon; William Capp
Link to Docket External link to docket
Small Molecule Drugs cited in Aventis Pharma S.A. v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Aventis Pharma S.A. v. Apotex Inc. (D. Del. 2008)

Date Filed Document No. Description Snippet Link To Document
2008-08-08 1 Complaint Paragraph IV certification”) alleging that U.S. Patent Nos. 4,814,470; 5,438,072; 5,698,582; 5,714,512; and 5,…et al. ............................ 424/278 4,814,470 3/1989 Coljn et al. 514/449 4,960.790 10/1990 Stella…. This is a civil action for patent infringement arising under the Patent Laws of the United States, 35…expiration of certain sanofi-aventis patents, including U.S. Patent Nos. 5,438,072, 5,698,582, 5,714,512… reference 28. United States Patent No. 5,714,512 Bl (“the ‘5 12 patent”), entitled “New Compositions External link to document
2008-09-22 21 as follows: U.S. Patent No. 4,814,470 (May l4, 2010) (the ’470 patent); U.S. Patent No. 5,698,582(Ju1y…018 certification against U.S. Patent No. 4,814,470 (the “’470 patent”), and thus irrespective of this… (the ’582 patent); U.s. Patent NO. 5,714,512(Ju1y 3, 2012) (the ’512 patent); U.S. Patent No. 5,750,561…2012) (the ’56l patent); and U.S. Patent No. 5,438,072 (Nov. 22, 2013) (the ’072 patent). Pursuant to …and ’561 patents and the Apotex action 2 The ’582 patent is the parent of the ’512 patent. Thus, the External link to document
2008-08-11 3 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,714,512; 5,750,561; (dzs, )… OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 5,714,512 …Apotex, Inc. et al PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT …REPORT ON THE TO: Director of the U.S. Patent and Trademark Office FILING External link to document
2008-08-27 8 Answer to Complaint records U.S. Patent No. 4,814,470 was commonly owned with the other four Orange Book Patents: first by Rhone…quot;V certification”) alleging that U.S. Patent Nos. 4,814,470; 5,438,072; 5,698,582; 5,714,5l2; and 5,…of the ‘072 patent and/or the ‘582 patent, along with the ‘5 12 patent and/or ‘561 patent 26. Nonetheless…limited States Patent and Tradernarl< Office issued U.S. Patent Nos. 5,714,512 (“the ‘512 patent”), 5,750,561… and/or ‘€)72 patents, namely, U.S`. Patent No. 4,-814,47{} issued to Colin, U.S. Patent No. 4,534,899 External link to document
2008-08-27 9 Answer to Complaint , and/or ‘(}72 patents narnely, U.S. Patent No. 4,814,470 issued to Colin, U.S. Patent l\lo. 4,534,899…records U.S. Patent No. 4,814,470 was commonly owned with the other four Orange Book Patents: first by Rhone-Poulenc…Paragraph lV certification”) alleging that U.S. Patent Nos. 4,814,470; 5,438,072; 5,698,582; 5,714,512; and 5,… of the ‘072 patent and/or the ‘582 patent, along with the ‘512 patent and/or ‘56l patent 26. Nonetheless…States Patent and ”i`rademarl< Oftice issued U.S'. Patent Nos. 5,714,512 (“the ‘512 patent”), 5, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
Mallinckrodt
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.